Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (427 views)
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.829, 5-year impact factor: 4.312
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33744945763&partnerID=40&md5=51dc9a8b5692da3293ca33a4a3ae0912
Keywords: Bone Pain, Combined Therapy, Sr-89, Zoledronic Acid, Bisphosphonic Acid Derivative, Strontium 89, Adult, Aged, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Clinical Article, Clinical Feature, Controlled Study, Female, Human, Infection, Nephrotoxicity, Pain Assessment, Patient Monitoring, Physician, Rating Scale, Statistical Significance, Visual Analog Scale, 80 And Over, Bone Neoplasms, Breast Neoplasms, Combined Modality Therapy, Diphosphonates, Follow-Up Studies, Imidazoles, Middle Aged, Neoplasm Metastasis, Palliative Care, Prostatic Neoplasms, Strontium Radioisotopes, Time Factors, Treatment Outcome,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy
Department of Biomorphological and Functional Sciences, University Federico II of Naples, Italy
Department of Oncology, University Federico II of Naples, Italy
IRCCS, Neuromed, Pozzilli, Italy
Diagnostic Imaging, University of Naples Parthenope, Italy
References:
Not available.
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.829, 5-year impact factor: 4.312
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33744945763&partnerID=40&md5=51dc9a8b5692da3293ca33a4a3ae0912
Keywords: Bone Pain, Combined Therapy, Sr-89, Zoledronic Acid, Bisphosphonic Acid Derivative, Strontium 89, Adult, Aged, Article, Bleeding, Blood Toxicity, Bone Marrow Suppression, Bone Metastasis, Clinical Article, Clinical Feature, Controlled Study, Female, Human, Infection, Nephrotoxicity, Pain Assessment, Patient Monitoring, Physician, Rating Scale, Statistical Significance, Visual Analog Scale, 80 And Over, Bone Neoplasms, Breast Neoplasms, Combined Modality Therapy, Diphosphonates, Follow-Up Studies, Imidazoles, Middle Aged, Neoplasm Metastasis, Palliative Care, Prostatic Neoplasms, Strontium Radioisotopes, Time Factors, Treatment Outcome,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy
Department of Biomorphological and Functional Sciences, University Federico II of Naples, Italy
Department of Oncology, University Federico II of Naples, Italy
IRCCS, Neuromed, Pozzilli, Italy
Diagnostic Imaging, University of Naples Parthenope, Italy
References:
Not available.
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
Purpose: We evaluated the pain response and daily discomfort in patients with painful bone metastases treated by merging 89Sr-chloride and zoledronic acid. The results were compared with those of patients who received 89Sr-chloride or zoledronic acid separately. Methods: 25 patients (12 women; mean age 65 ± 13 years) chronically treated with zoledronic acid underwent bone pain palliation with 150 MBq of 89Sr-chloride at least 6 months later that bisphoshonate therapy started (group A). 13 patients (6 women; mean age 70 ± 12 years) received 89Sr-chloride alone (group B) and 11 patients (5 women; mean age 69 ± 12 years) were chronically treated and continued to receive only zoledronic acid therapy (group C), both constituted the control groups. Patients kept a daily pain diary assessing both their discomfort and the pain of specific sites by using a visual analog scale (VAS), rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three different physicians rated the pain response on a scale of -2 (considerable deterioration) to +2 (considerable improvement). Results: Baseline characteristics were similar in the three groups. The reduction of total discomfort and of bone pain in the group A was significantly greater as compared to group B (P < 0.01) and group C (P < 0.01). During the monitored period, a significant improvement of clinical conditions was observed in the group A, varying the rate from -1 to 1 as compared to both groups B and C in which the rate changed from -1 to 0. Conclusion: Our findings indicate that combined therapy of 89Sr-chloride and zoledronic acid in patients with painful bone metastases is more effective in treating pain and improving clinical conditions than 89Sr-chloride or zoledronic acid used separately. © 2005 Elsevier Inc. All rights reserved.
Purpose: We evaluated the pain response and daily discomfort in patients with painful bone metastases treated by merging 89Sr-chloride and zoledronic acid. The results were compared with those of patients who received 89Sr-chloride or zoledronic acid separately. Methods: 25 patients (12 women; mean age 65 ± 13 years) chronically treated with zoledronic acid underwent bone pain palliation with 150 MBq of 89Sr-chloride at least 6 months later that bisphoshonate therapy started (group A). 13 patients (6 women; mean age 70 ± 12 years) received 89Sr-chloride alone (group B) and 11 patients (5 women; mean age 69 ± 12 years) were chronically treated and continued to receive only zoledronic acid therapy (group C), both constituted the control groups. Patients kept a daily pain diary assessing both their discomfort and the pain of specific sites by using a visual analog scale (VAS), rating from 0 (no discomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three different physicians rated the pain response on a scale of -2 (considerable deterioration) to +2 (considerable improvement). Results: Baseline characteristics were similar in the three groups. The reduction of total discomfort and of bone pain in the group A was significantly greater as compared to group B (P < 0.01) and group C (P < 0.01). During the monitored period, a significant improvement of clinical conditions was observed in the group A, varying the rate from -1 to 1 as compared to both groups B and C in which the rate changed from -1 to 0. Conclusion: Our findings indicate that combined therapy of 89Sr-chloride and zoledronic acid in patients with painful bone metastases is more effective in treating pain and improving clinical conditions than 89Sr-chloride or zoledronic acid used separately. © 2005 Elsevier Inc. All rights reserved.
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
No results. |
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
Other filter: ([btitle,keywords] "Combined Therapy" OR ...
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (447 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (415 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (355 views) (PDF 12 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (327 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (368 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B
* Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans (454 views)
Leuk Lymphoma (ISSN: 1042-8194, 1026-8022linking), 2007 Sep; 48(9): 1721-1727.
Impact Factor: 1.512
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (475 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Paone G, Klain M, Salvatore B, Capacchione D, Soricelli A, Pace L, Salvatore M
* Hematological Toxicity in Patients with Painful Bone Metastases Treated with Sr-89 and Zoledronic Acid (214 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Storto G, Paone G, Ibello F, Klain M, Liuzzi R, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (299 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (373 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (447 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (415 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (355 views) (PDF 12 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (327 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (368 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B
* Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans (454 views)
Leuk Lymphoma (ISSN: 1042-8194, 1026-8022linking), 2007 Sep; 48(9): 1721-1727.
Impact Factor: 1.512
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (475 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Paone G, Klain M, Salvatore B, Capacchione D, Soricelli A, Pace L, Salvatore M
* Hematological Toxicity in Patients with Painful Bone Metastases Treated with Sr-89 and Zoledronic Acid (214 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View Export to BibTeX Export to EndNote
Storto G, Paone G, Ibello F, Klain M, Liuzzi R, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (299 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (373 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
10 Records (7 excluding Abstracts).
Total impact factor: 29.434 (19.208 excluding Abstracts).
Total 5 year impact factor: 32.102 (20.188 excluding Abstracts).
Total impact factor: 29.434 (19.208 excluding Abstracts).
Total 5 year impact factor: 32.102 (20.188 excluding Abstracts).
427 views. Last view on Monday 13 November 2023, 16:30:57
ibb.cnr.it
